Yu-Tao Guo

List of Publications by Year
in descending order

68 papers	5,620 citations	257450 24 h-index	110387 64 g-index
74 all docs	74 docs citations	74 times ranked	9721 citing authors

#	Article	IF	Citations
1	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. Journal of the American College of Cardiology, 2020, 75, 2950-2973.	2.8	2,392
2	Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation. Journal of the American College of Cardiology, 2019, 74, 2365-2375.	2.8	294
3	Prevalence, Incidence, and Lifetime Risk of Atrial Fibrillation in China. Chest, 2015, 147, 109-119.	0.8	219
4	Adherence to the â€˜Atrial Fibrillation Better Careâ€™ Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomesâ€”A Systematic Review and Meta-Analysis of 285,000 Patients. Thrombosis and Haemostasis, 2022, 122, 406-414.	3.4	219
5	Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke. Stroke, 2020, 51, e254-e258.	2.0	213
6	Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2020, 75, 1523-1534.	2.8	209
7	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis and Haemostasis, 2020, 120, 1004-1024.	3.4	206
8	2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. Thrombosis and Haemostasis, 2022, 122, 020-047.	3.4	192
9	Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial. American Journal of Medicine, 2017, 130, 1388-1396.e6.	1.5	172
10	A Simple Clinical Risk Score (C2HEST) for Predicting Incident Atrial Fibrillation in AsianÂSubjects. Chest, 2019, 155, 510-518.	0.8	124
11	mHealth For Aging China: Opportunities and Challenges. , 2016, 7, 53.		94
12	Mobile health technology-supported atrial fibrillation screening and integrated care: A report from the mAFA-II trial Long-term Extension Cohort. European Journal of Internal Medicine, 2020, 82, 105-111.	2.2	94
13	Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic. European Journal of Preventive Cardiology, 2021, 28, 1599-1609.	1.8	93
14	Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial. American Journal of Medicine, 2020, 133, 1195-1202.e2.	1.5	80
15	European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). Europace, 2019, 21, 7-8.	1.7	72
16	Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation. International Journal of Cardiology, 2013, 168, 904-909.	1.7	67
17	Epidemiology of Atrial Fibrillation. Cardiac Electrophysiology Clinics, 2021, 13, 1-23.	1.7	63
18	Diagnostic Performance of a Smart Device With Photoplethysmography Technology for Atrial Fibrillation Detection: Pilot Study (Pre-mAFA II Registry). JMIR MHealth and UHealth, 2019, 7, e11437.	3.7	58

#	Article	IF	Citations
19	Mobile Health (mHealth) technology for improved screening, patient involvement and optimising integrated care in atrial fibrillation: The mAFA (mAFâ€App) II randomised trial. International Journal of Clinical Practice, 2019, 73, e13352.	1.7	56
20	Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. International Journal of Cardiology, 2013, 168, 4678-4684.	1.7	52
21	Comparing Bleeding Risk Assessment Focused on Modifiable Risk Factors Only Versus Validated Bleeding Risk Scores in Atrial Fibrillation. American Journal of Medicine, 2018, 131, 185-192.	1.5	49
22	Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation. Chest, 2015, 148, 62-72.	0.8	40
23	2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. Journal of Arrhythmia, 2021, 37, 1389-1426.	1.2	38
24	Risk factors for new-onset atrial fibrillation: A focus on Asian populations. International Journal of Cardiology, 2018, 261, 92-98.	1.7	37
25	Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: Would the novel oral anticoagulants have an impact?. International Journal of Cardiology, 2013, 168, 515-522.	1.7	35
26	The Effects of Implementing a Mobile Healthâ€"Technology Supported Pathway on Atrial Fibrillationâ€"Related Adverse Events Among Patients With Multimorbidity. JAMA Network Open, 2021, 4, e2140071.	5.9	27
27	Multiple risk factors and ischaemic stroke in the elderly Asian population with and without atrial fibrillation. Thrombosis and Haemostasis, 2016, 115, 184-192.	3.4	26
28	Validation of Single Centre Pre-Mobile Atrial Fibrillation Apps for Continuous Monitoring of Atrial Fibrillation in a Real-World Setting: Pilot Cohort Study. Journal of Medical Internet Research, 2019, 21, e14909.	4.3	26
29	Relation of renal dysfunction to the increased risk of stroke and death in female patients with atrial fibrillation. International Journal of Cardiology, 2013, 168, 1502-1508.	1.7	25
30	Assessing bleeding risk in 4824 Asian patients with atrial fibrillation: The Beijing PLA Hospital Atrial Fibrillation Project. Scientific Reports, 2016, 6, 31755.	3.3	23
31	Effects of Body Mass Index on Risks for Ischemic Stroke, Thromboembolism, and Mortality in Chinese Atrial Fibrillation Patients: A Single-Center Experience. PLoS ONE, 2015, 10, e0123516.	2.5	23
32	Population-Based Screening or Targeted Screening Based on Initial Clinical Risk Assessment for Atrial Fibrillation: A Report from the Huawei Heart Study. Journal of Clinical Medicine, 2020, 9, 1493.	2.4	21
33	4Sâ€AF scheme and ABC pathway guided management improves outcomes in atrial fibrillation patients. European Journal of Clinical Investigation, 2022, 52, e13751.	3.4	20
34	Mobile health technology in atrial fibrillation. Expert Review of Medical Devices, 2022, 19, 327-340.	2.8	19
35	â€˜Real-worldâ€™ observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). Europace, 2020, 22, 831-832.	1.7	18
36	Poor adherence to guideline-directed anticoagulation in elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. European Heart Journal Quality of Care & Clinical Outcomes, 2023, 9, 169-176.	4.0	18

#	Article	IF	Citations
37	Antithrombotic therapy in very elderly patients with atrial fibrillation: Is it enough to assess thromboembolic risk?. Clinical Interventions in Aging, 2010, 5, 157.	2.9	15
38	Risk factors for systemic and venous thromboembolism, mortality and bleeding risks in 1125 patients with COVID-19: relationship with anticoagulation status. Aging, 2021, 13, 9225-9242.	3.1	15
39	Apremilast ameliorates ox-LDL-induced endothelial dysfunction mediated by KLF6. Aging, 2020, 12, 19012-19021.	3.1	15
40	Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry: protocol for a prospective, observational nationwide cohort study. BMJ Open, 2018, 8, e020191.	1.9	14
41	Should We Adopt a Standard International Normalized Ratio Range of 2.0 to 3.0 for Asian Patients with Atrial Fibrillation? An Appeal for Evidence-Based Management, Not Eminence-Based Recommendations. Thrombosis and Haemostasis, 2020, 120, 366-368.	3.4	12
42	Application of cardiac computed tomographic imaging and fluoroscopy fusion for guiding left atrial appendage occlusion. International Journal of Cardiology, 2021, 331, 289-295.	1.7	12
43	A New Paradigm of â€œReal-Timeâ€•Stroke Risk Prediction and Integrated Care Management in the Digital Health Era: Innovations Using Machine Learning and Artificial Intelligence Approaches. Thrombosis and Haemostasis, 2022, 122, 005-007.	3.4	12
44	Mobile health technology facilitates population screening and integrated care management in patients with atrial fibrillation. European Heart Journal, 2020, 41, 1617-1619.	2.2	10
45	Photoplethysmography-Based MachineÂLearning Approaches for AtrialÂFibrillation Prediction. JACC Asia, 2021, 1, 399-408.	1.5	10
46	Identification of microRNA biomarkers in serum of patients at different stages of atrial fibrillation. Heart and Lung: Journal of Acute and Critical Care, 2020, 49, 902-908.	1.6	8
47	Importance of attributes and willingness to pay for oral anticoagulant therapy in patients with atrial fibrillation in China: A discrete choice experiment. PLoS Medicine, 2021, 18, e1003730.	8.4	8
48	Quality indicators in the management of elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 651-658.	4.0	8
49	Oral anticoagulation improves survival in very elderly Chinese patients with atrial fibrillation: A report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. International Journal of Stroke, 2022, 17, 661-668.	5.9	8
50	Relations between left atrial appendage contrast retention and thromboembolic risk in patients with atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2022, 53, 191-201.	2.1	7
51	Mobile Health for Cardiovascular Disease: The New Frontier for AF Management: Observations from the Huawei Heart Study and mAFA-II Randomised Trial. Arrhythmia and Electrophysiology Review, 2020, 9, 5-7.	2.4	6
52	The Challenge of Antiplatelet Therapy in Patients with Atrial Fibrillation and Heart Failure. Journal of Cardiovascular Translational Research, 2013, 6, 388-397.	2.4	5
53	Determinants and Time Trends for Ischaemic and Haemorrhagic Stroke in a Large Chinese Population. PLoS ONE, 2016, 11, e0163171.	2.5	4
54	Vital Signs During the COVID-19 Outbreak: A Retrospective Analysis of 19,960 Participants in Wuhan and Four Nearby Capital Cities in China. Global Heart, 2021, 16, 47.	2.3	4

#	Article	IF	Citations
55	The unmet need of stroke prevention in atrial fibrillation in the far East and South East Asia. The Malaysian Journal of Medical Sciences, 2012, 19, 1-7.	0.5	4
56	Resistin might not be a risk factor for carotid artery atherosclerosis in elderly Chinese males. Journal of Geriatric Cardiology, 2014, 11, 222-8.	0.2	4
57	Medical treatment and long-term outcome of chronic atrial fibrillation in the aged with chest distress: a retrospective analysis versus sinus rhythm. Clinical Interventions in Aging, 2011, 6, 193.	2.9	3
58	Embolic Stroke of Undetermined Source: The Need for an Integrated and Holistic Approach to Care. Thrombosis and Haemostasis, 2021, 121, 251-254.	3.4	3
59	Beyond atrial fibrillation detection: how digital tools impact the care of patients with atrial fibrillation. European Journal of Internal Medicine, 2021, 93, 117-118.	2.2	3
60	Long-term outcomes of high-risk elderly male patients with multivessel coronary disease: optimal medical therapy versus revascularization. Journal of Geriatric Cardiology, 2016, 13, 152-7.	0.2	3
61	A risk prediction score model for predicting occurrence of post-PCI vasovagal reflex syndrome: a single center study in Chinese population. Journal of Geriatric Cardiology, 2017, 14, 509-514.	0.2	3
62	Digoxin use and clinical outcomes in elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. Europace, 2022, 24, 1076-1083.	1.7	3
63	The potential for photoplethysmographic (PPG)-based smart devices in atrial fibrillation detection. Expert Review of Medical Devices, 2020, 17, 253-255.	2.8	2
64	Outcomes in elderly Chinese patients with atrial fibrillation and coronary artery disease. A report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (<scp>ChiOTEAF</scp>) registry. Journal of Arrhythmia, 2022, 38, 580-588.	1.2	2
65	Letter by Guo et al Regarding Article, â€œEffectiveness of an mHealth-Based Electronic Decision Support System for Integrated Management of Chronic Conditions in Primary Care: The mWellcare Cluster-Randomized Controlled Trialâ€• Circulation, 2019, 139, e1037-e1038.	1.6	1
66	Lifestyle and risk factor modification for reduction of atrial fibrillation: We could do more. Trends in Cardiovascular Medicine, 2020, 30, 387-388.	4.9	1
67	Letter by Guo et al Regarding Article, â€œSUPPORT-AF II: Supporting Use of Anticoagulants Through Provider Profiling of Oral Anticoagulant Therapy for Atrial Fibrillationâ€• Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006635.	2.2	0
68	Reply. Journal of the American College of Cardiology, 2020, 75, 1366-1367.	2.8	0